| MeSH term | MeSH ID | Detail |
|---|---|---|
| Tick Bites | D064927 | 1 associated lipids |
| Chlamydial Pneumonia | D061387 | 2 associated lipids |
| Reproductive Tract Infections | D060737 | 1 associated lipids |
| Granulomatous Mastitis | D058890 | 1 associated lipids |
| Trichiasis | D058457 | 1 associated lipids |
| Asymptomatic Infections | D058345 | 1 associated lipids |
| Acute Kidney Injury | D058186 | 34 associated lipids |
| Neglected Diseases | D058069 | 3 associated lipids |
| Corneal Endothelial Cell Loss | D055954 | 1 associated lipids |
| Multiple Pulmonary Nodules | D055613 | 2 associated lipids |
| Acute Lung Injury | D055371 | 33 associated lipids |
| Failed Back Surgery Syndrome | D055111 | 3 associated lipids |
| Tracheobronchomalacia | D055089 | 1 associated lipids |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | D054198 | 10 associated lipids |
| Hyper-IgM Immunodeficiency Syndrome | D053306 | 1 associated lipids |
| Pyomyositis | D052880 | 2 associated lipids |
| Male Urogenital Diseases | D052801 | 1 associated lipids |
| Tendinopathy | D052256 | 3 associated lipids |
| Mucositis | D052016 | 7 associated lipids |
| Pyloric Stenosis, Hypertrophic | D046248 | 2 associated lipids |
| Moraxellaceae Infections | D045828 | 3 associated lipids |
| Desulfovibrionaceae Infections | D045824 | 5 associated lipids |
| Pulmonary Disease, Chronic Obstructive | D029424 | 16 associated lipids |
| Chlamydophila Infections | D023521 | 4 associated lipids |
| Communicable Diseases, Emerging | D021821 | 3 associated lipids |
| Central Nervous System Protozoal Infections | D020808 | 3 associated lipids |
| Multiple Sclerosis, Relapsing-Remitting | D020529 | 7 associated lipids |
| Focal Nodular Hyperplasia | D020518 | 1 associated lipids |
| Neurotoxicity Syndromes | D020258 | 34 associated lipids |
| Acquired Hyperostosis Syndrome | D020083 | 1 associated lipids |
| Syncope, Vasovagal | D019462 | 1 associated lipids |
| Pouchitis | D019449 | 3 associated lipids |
| Pseudolymphoma | D019310 | 1 associated lipids |
| Gingival Overgrowth | D019214 | 7 associated lipids |
| Abdominal Abscess | D018784 | 2 associated lipids |
| Parasitemia | D018512 | 5 associated lipids |
| Pneumonia, Bacterial | D018410 | 16 associated lipids |
| T-Lymphocytopenia, Idiopathic CD4-Positive | D018344 | 1 associated lipids |
| Furcation Defects | D017823 | 1 associated lipids |
| Granuloma, Pyogenic | D017789 | 2 associated lipids |
| Community-Acquired Infections | D017714 | 8 associated lipids |
| Pelvic Pain | D017699 | 7 associated lipids |
| Aortic Aneurysm, Abdominal | D017544 | 5 associated lipids |
| Pityriasis Rosea | D017515 | 3 associated lipids |
| Skin Diseases, Bacterial | D017192 | 8 associated lipids |
| AIDS-Related Opportunistic Infections | D017088 | 9 associated lipids |
| Common Variable Immunodeficiency | D017074 | 4 associated lipids |
| Gram-Negative Bacterial Infections | D016905 | 16 associated lipids |
| Neisseriaceae Infections | D016870 | 3 associated lipids |
| Ureaplasma Infections | D016869 | 5 associated lipids |
Azithramycine
Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.
Cross Reference
Introduction
To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with Azithramycine?
Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (156)
- Clin. Infect. Dis. (64)
- J. Antimicrob. Chemother. (50)
- Others (435)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with Azithramycine
PubChem Associated disorders and diseases
What pathways are associated with Azithramycine
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with Azithramycine?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (66)
- J. Antimicrob. Chemother. (25)
- Clin. Infect. Dis. (13)
- Others (151)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with Azithramycine?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with Azithramycine?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with Azithramycine?
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (44)
- J. Antimicrob. Chemother. (18)
- Clin. Infect. Dis. (10)
- Others (126)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with Azithramycine?
Mouse Model
Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).
Knock-out
Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).
Tissue Model
Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with Azithramycine
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Parry CM et al. | Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. | 2007 | Antimicrob. Agents Chemother. | pmid:17145784 |
| Rodvold KA et al. | Intrapulmonary steady-state concentrations of clarithromycin and azithromycin in healthy adult volunteers. | 1997 | Antimicrob. Agents Chemother. | pmid:9174209 |
| Donowitz GR and Earnhardt KI | Azithromycin inhibition of intracellular Legionella micdadei. | 1993 | Antimicrob. Agents Chemother. | pmid:8285604 |
| Hauser C et al. | In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates. | 2015 | Antimicrob. Agents Chemother. | pmid:25547354 |
| Bermudez LE et al. | Stimulation with cytokines enhances penetration of azithromycin into human macrophages. | 1991 | Antimicrob. Agents Chemother. | pmid:1667256 |
| Saiz JC and MartÃn-Acebes MA | Reply to Iannetta et al., "Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells". | 2017 | Antimicrob. Agents Chemother. | pmid:28839084 |
| Iannetta M et al. | Azithromycin Shows Anti-Zika Virus Activity in Human Glial Cells. | 2017 | Antimicrob. Agents Chemother. | pmid:28839081 |
| Feola DJ et al. | Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. | 2010 | Antimicrob. Agents Chemother. | pmid:20231397 |
| Hultén K et al. | New pharmacokinetic in vitro model for studies of antibiotic activity against intracellular microorganisms. | 1996 | Antimicrob. Agents Chemother. | pmid:9124830 |
| Bui KQ et al. | Mononuclear and polymorphonuclear leukocyte dispositions of clarithromycin and azithromycin in AIDS patients requiring Mycobacterium avium complex prophylaxis. | 1999 | Antimicrob. Agents Chemother. | pmid:10471584 |
| Zarantonelli L et al. | Decreased azithromycin susceptibility of Neisseria gonorrhoeae due to mtrR mutations. | 1999 | Antimicrob. Agents Chemother. | pmid:10508026 |
| Zhanel GG et al. | Mutant prevention concentrations of levofloxacin alone and in combination with azithromycin, ceftazidime, colistin (Polymyxin E), meropenem, piperacillin-tazobactam, and tobramycin against Pseudomonas aeruginosa. | 2006 | Antimicrob. Agents Chemother. | pmid:16723591 |
| Wierzbowski AK et al. | Expression of the mef(E) gene encoding the macrolide efflux pump protein increases in Streptococcus pneumoniae with increasing resistance to macrolides. | 2005 | Antimicrob. Agents Chemother. | pmid:16251306 |
| Jesus FP et al. | In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. | 2014 | Antimicrob. Agents Chemother. | pmid:25001300 |
| Miura Y et al. | Maternal intravenous treatment with either azithromycin or solithromycin clears Ureaplasma parvum from the amniotic fluid in an ovine model of intrauterine infection. | 2014 | Antimicrob. Agents Chemother. | pmid:24982089 |
| Kohlhoff SA et al. | In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. | 2004 | Antimicrob. Agents Chemother. | pmid:15105151 |
| Brieland JK et al. | Efficacy of SCH27899 in an animal model of Legionnaires' disease using immunocompromised A/J mice. | 2000 | Antimicrob. Agents Chemother. | pmid:10770771 |
| Luke DR et al. | Safety, toleration, and pharmacokinetics of intravenous azithromycin. | 1996 | Antimicrob. Agents Chemother. | pmid:8913468 |
| Waites KB et al. | In Vitro Activities of Omadacycline (PTK 0796) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. | 2016 | Antimicrob. Agents Chemother. | pmid:27671057 |
| Olsen KM et al. | Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. | 1996 | Antimicrob. Agents Chemother. | pmid:8913469 |
| Hogan PA and Sheehan DJ | Macrolide susceptibility and beta-lactamase production among haemophilus influenzae isolates in the United States, 1996-1997. | 1998 | Antimicrob. Agents Chemother. | pmid:9835536 |
| Gillis RJ et al. | Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms. | 2005 | Antimicrob. Agents Chemother. | pmid:16127063 |
| RÃos AM et al. | Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia. | 2005 | Antimicrob. Agents Chemother. | pmid:16127085 |
| Berry V et al. | Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae. | 2005 | Antimicrob. Agents Chemother. | pmid:15728883 |
| GarcÃa-Quintanilla M et al. | Inhibition of LpxC Increases Antibiotic Susceptibility in Acinetobacter baumannii. | 2016 | Antimicrob. Agents Chemother. | pmid:27270288 |
| Noedl H et al. | In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome. | 2007 | Antimicrob. Agents Chemother. | pmid:17116669 |
| Beale AS and Upshon PA | Characteristics of murine model of genital infection with Chlamydia trachomatis and effects of therapy with tetracyclines, amoxicillin-clavulanic acid, or azithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:7811001 |
| Pruul H and McDonald PJ | Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. | 1992 | Antimicrob. Agents Chemother. | pmid:1317141 |
| Yeruva L et al. | Differential susceptibilities to azithromycin treatment of chlamydial infection in the gastrointestinal tract and cervix. | 2013 | Antimicrob. Agents Chemother. | pmid:24100498 |
| Spangler SK et al. | Effect of CO2 on susceptibilities of anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin. | 1994 | Antimicrob. Agents Chemother. | pmid:8192445 |
| Stamler DA et al. | Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. | 1994 | Antimicrob. Agents Chemother. | pmid:8192446 |
| Reveneau N et al. | Bactericidal activity of first-choice antibiotics against gamma interferon-induced persistent infection of human epithelial cells by Chlamydia trachomatis. | 2005 | Antimicrob. Agents Chemother. | pmid:15855497 |
| Mizukane R et al. | Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa. | 1994 | Antimicrob. Agents Chemother. | pmid:8203850 |
| Seral C et al. | Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. | 2003 | Antimicrob. Agents Chemother. | pmid:12821480 |
| Araujo FG and Remington JS | Synergistic activity of azithromycin and gamma interferon in murine toxoplasmosis. | 1991 | Antimicrob. Agents Chemother. | pmid:1656872 |
| Taylor DE and Chang N | In vitro susceptibilities of Campylobacter jejuni and Campylobacter coli to azithromycin and erythromycin. | 1991 | Antimicrob. Agents Chemother. | pmid:1659309 |
| Wingard JB et al. | A novel cell-associated protection assay demonstrates the ability of certain antibiotics to protect ocular surface cell lines from subsequent clinical Staphylococcus aureus challenge. | 2011 | Antimicrob. Agents Chemother. | pmid:21628536 |
| Plouffe J et al. | Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. | 2000 | Antimicrob. Agents Chemother. | pmid:10858333 |
| Skindersoe ME et al. | Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. | 2008 | Antimicrob. Agents Chemother. | pmid:18644954 |
| Jesus FP et al. | In Vitro and In Vivo Antimicrobial Activities of Minocycline in Combination with Azithromycin, Clarithromycin, or Tigecycline against Pythium insidiosum. | 2015 | Antimicrob. Agents Chemother. | pmid:26459895 |
| Salman S et al. | Optimal Antimalarial Dose Regimens for Sulfadoxine-Pyrimethamine with or without Azithromycin in Pregnancy Based on Population Pharmacokinetic Modeling. | 2017 | Antimicrob. Agents Chemother. | pmid:28242669 |
| Unemo M et al. | High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. | 2015 | Antimicrob. Agents Chemother. | pmid:26077246 |
| Pereira MR et al. | In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine. | 2011 | Antimicrob. Agents Chemother. | pmid:21464242 |
| Bogdanovich T et al. | Effect of efflux on telithromycin and macrolide susceptibility in Haemophilus influenzae. | 2006 | Antimicrob. Agents Chemother. | pmid:16495248 |
| Lai PC and Walters JD | Azithromycin kills invasive Aggregatibacter actinomycetemcomitans in gingival epithelial cells. | 2013 | Antimicrob. Agents Chemother. | pmid:23274657 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |
| Ouadrhiri Y et al. | Mechanism of the intracellular killing and modulation of antibiotic susceptibility of Listeria monocytogenes in THP-1 macrophages activated by gamma interferon. | 1999 | Antimicrob. Agents Chemother. | pmid:10223943 |
| Könönen E et al. | beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children. | 1999 | Antimicrob. Agents Chemother. | pmid:10223950 |
| Soares GM et al. | Effects of azithromycin, metronidazole, amoxicillin, and metronidazole plus amoxicillin on an in vitro polymicrobial subgingival biofilm model. | 2015 | Antimicrob. Agents Chemother. | pmid:25733510 |
| Parry CM et al. | Clinically and microbiologically derived azithromycin susceptibility breakpoints for Salmonella enterica serovars Typhi and Paratyphi A. | 2015 | Antimicrob. Agents Chemother. | pmid:25733500 |